SCHEMBL20292802

SCHEMBL20292802

O=Cc1cnc2[nH]cc(I)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 2/20 0.45
BRD4 O60885 1/20 0.43
KMT2A Q03164 1/20 0.40
MAPK1 P28482 1/20 0.38
GSK3B P49841 9/20 0.36
CDK8 P49336 2/20 0.35
TNIK Q9UKE5 1/20 0.35
BRAF P15056 1/20 0.34
JAK2 O60674 2/20 0.33
DYRK1A Q13627 2/20 0.33
PLK4 O00444 1/20 0.33
AURKA O14965 1/20 0.33
ROCK2 O75116 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
PRKCG P05129 1/20 0.33
INSR P06213 1/20 0.33
CDK1 P06493 1/20 0.33
FES P07332 1/20 0.33
IGF1R P08069 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29951120 1.00 AXL (0.45) AXLBRD4KMT2AMAPK1GSK3B
SCHEMBL24764929 0.82 KMT2A (0.54) AXLBRD4KMT2AGSK3BCDK8
SCHEMBL20319048 0.79 MET (0.44) AXLKMT2ABRAFITKPTGER4
SCHEMBL22517081 0.79 PRMT5 (0.42) AXLKMT2AGSK3BCDK8TNIK
SCHEMBL18371565 0.79 BTK (0.42) AXLKMT2AJAK2ITK
SCHEMBL29955771 0.79 AXL (0.43) AXLKMT2AMAPK1GSK3BCDK8
SCHEMBL17939084 0.78 AXL (0.71) AXLBRD4MAPK1GSK3BCDK8
SCHEMBL29952518 0.76 AXL (0.70) AXLMAPK1GSK3BCDK8TNIK
SCHEMBL15241762 0.76 BRD4 (0.49) AXLBRD4MAPK1GSK3BCDK8
SCHEMBL29954974 0.74 AXL (0.39) AXLKMT2ADYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692089-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AS AAK1 INHIBITOR Alicorn Pharmaceutical Co., Ltd. (CN) 2026-02-11 EP disclosed
WO-2024207945-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AS AAK1 INHIBITOR 艾立康药业股份有限公司 2024-10-10 WO disclosed
EP-4415817-A1 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 EP disclosed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 US disclosed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 US disclosed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 US disclosed
EP-4183786-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES Felicitex Therapeutics, Inc. (US) 2023-05-24 EP disclosed
EP-4183786-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES Felicitex Therapeutics, Inc. (US) 2023-05-24 EP disclosed
WO-2023064349-A1 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
EP-3558321-B1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS INC (US) 2023-02-01 EP disclosed
EP-3558321-B1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS INC (US) 2023-02-01 EP disclosed
US-10577365-B2 Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases FELICITEX THERAPEUTICS, INC. (US) 2020-03-03 US disclosed
US-10577365-B2 Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases FELICITEX THERAPEUTICS, INC. (US) 2020-03-03 US disclosed
EP-3558321-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES Felicitex Therapeutics, Inc. (US) 2019-10-30 EP disclosed
WO-2018119039-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 WO disclosed
US-20180179199-A1 DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 US disclosed
US-20180179199-A1 DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 US disclosed
US-20180179199-A1 DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 US disclosed
WO-2018119039-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 AXL 1433/4885BRD4 394/4885KMT2A 1738/4885
US-10577365-B2 Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases DYRK1A, DYRK1B, DYRK2 AXL 875/4885BRD4 736/4885KMT2A 695/4885
US-20180179199-A1 DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES DYRK1A, DYRK1B, DYRK2 AXL 875/4885BRD4 736/4885KMT2A 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.